期刊文献+

胃肠间质瘤术后复发影响因素分析及治疗决策展望 被引量:6

Analysis of factors influencing postoperative recurrence of gastrointestinal stromal tumors and prospects for treatment decision
下载PDF
导出
摘要 胃肠道间质瘤唯一可能治愈的手段是外科手术,但是术后复发或转移的风险无法忽视,根据术后风险评估进行靶向治疗是预防复发或转移的关键。影响胃肠道间质瘤术后复发的因素很多,肿瘤大小、肿瘤部位、核分裂像以及肿瘤破裂被认为是独立的危险因素,并根据这些因素制定有风险评估方法,主要包括F/NIH分级标准、AFIP分级标准、2008年改良的NIH分级标准以及列线图模型。虽然这些评估方法确定了预后危险因素指标和危险程度分级,但是均无法准确地评估患者术后复发风险概率,指导临床的准确治疗。因此,我们仍需不断探索影响GIST的预后独立危险因素,建立简单准确的临床评估方法,提高复发风险概率预测的准确性,更好地指导临床个体化治疗,做到精准治疗。 The only possible cure for gastrointestinal stromal tumors is surgery,but the risk of recurrence or metastasis cannot be ignored.Targeted treatment based on postoperative risk assessment is the key to preventing recurrence or metastasis.There are many factors affecting the recurrence of gastrointestinal stromal tumors.Tumor size,tumor location,mitotic figures and tumor rupture are considered to be independent risk factors.According to these criteria,risk assessment methods are developed,mainly including F/NIH grading standards.AFIP grading standards,improved NIH grading standards in 2008,and nomogram models.Although these assessment methods have determined prognostic risk factors and risk grades,they are not able to accurately assess the risk of postoperative recurrence and guide clinical accurate treatment.Therefore,we still need to continuously explore the independent risk factors affecting the prognosis of GIST,establish a simple and accurate clinical evaluation method,improve the probability of recurrence risk probability,better guide clinical individualized treatment,and achieve precise treatment.
作者 田华开 宗振 TIAN Huakai;ZONG Zhen(Department of General Surgery,the Second Affiliated Hospital,Nanchang University,Nanchang 330006,China)
出处 《岭南现代临床外科》 2019年第6期658-661,共4页 Lingnan Modern Clinics in Surgery
基金 江西省卫计委科技计划(20172020)
关键词 胃肠道间质瘤 术后复发 危险因素 风险评估 腹腔内脂肪比例 gastrointestinal stromal tumor postoperative recurrence risk factors risk assessment intraperitoneal fat ratio
  • 相关文献

参考文献8

二级参考文献72

  • 1高峰,吴云林.胃肠道间质瘤的研究进展[J].上海第二医科大学学报,2005,25(9):889-893. 被引量:8
  • 2廖世兵,秦叔逵,杨柳青,邵志坚,王琳,何泽明.甲磺酸伊马替尼治疗国人胃肠间质瘤的临床研究[J].肿瘤防治研究,2005,32(9):539-541. 被引量:24
  • 3詹文华,王鹏志,邵永孚,伍晓汀,顾晋,李荣,万德森,丁克峰,师英强,于吉人,卢辉山,邹小明,毕建威,孙益红,陆云飞,陈道达,张信华.伊马替尼术后辅助治疗胃肠间质瘤的多中心前瞻性临床试验中期报告[J].中华胃肠外科杂志,2006,9(5):383-387. 被引量:85
  • 4梁玉梅,李向红,吕有勇,吕亚莉,钟梅,蒲小璐,李文梅.胃肠道间质瘤156例临床病理学特征与预后的分析[J].中华病理学杂志,2007,36(4):233-238. 被引量:15
  • 5Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279(5350) :577-580.
  • 6McGrath PC, Neifeld JP, Lawrence W Jr, et al. Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg, 1987, 206 (6) :706-710.
  • 7Hasegawa T, Matsuno Y, Shimoda T, et al. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol, 2002, 33(6) :669-676.
  • 8Gutierrez JC, De Oliveira LO, Perez EA, et al. Optimizing diagnosis, staging, and management of gastrointestinal stromal tumors. J Am Coil Surg, 2007, 205 (3) :479-491.
  • 9Trupiano JK, Stewart RE, Misick C, et al. Gastric stromal tumors: a clinicopathologic study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors. Am J Surg Pathol, 2002, 26(6) :705-714.
  • 10Yan H, Marchettini P, Acherman YI, et al. Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol, 2003,26 (3) : 221-228.

共引文献263

同被引文献70

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部